The DTM5 is a concentrated investment strategy focused on early-stage publicly traded and private ventures across sectors such as Technology, Health Care, Pharma, and Finance. The strategy evaluates opportunities based on Merit and Asymmetry, applies a Time and Price discipline to capital allocation, and emphasizes the presence of a Catalyst—the action, event, or constraint that enables value realization. Investment targets are often special situations where mispricing is created by structural or financial impairments that are misinterpreted by the market.

The number of investments held within the strategy is intentionally limited, typically five at a time. The DTM5’s Emerging Ventures focus targets companies that are often earlier stage, nano, micro, or small capitalization, and frequently pre-revenue or pre-profitability—areas that tend to sit outside the focus and comfort level of most investors.

From time to time, the DTM5 will also invest opportunistically in more established / mature companies.

Although I am a ‘long only’ investor, I take profits, cut losses, de-risk, pivot, trade and do a lot of simple waiting and watching. I can believe in a stock’s potential but sit on the sidelines. There is nothing I like more than to be in a situation where i can just ‘buy and hold’. But the reality of the types of companies I invest in necessitates a more flexible approach. Not just for potential return, but survival.

This blog exists to synthesize ideas, document thinking, test assumptions, and improve process over time. It is not monetized. I’m not selling anything, promoting a fund, or marketing a book. Comments, questions, and thoughtful challenges are always welcome.

For a deeper explanation of the framework and philosophy, see the full post: “What Is the DTM5?”

What is the DTM5 Strategy?